Grail, Inc. (NASDAQ:GRAL - Get Free Report) shares rose 9.1% during trading on Tuesday . The company traded as high as $43.49 and last traded at $43.85. Approximately 298,354 shares traded hands during trading, a decline of 76% from the average daily volume of 1,252,401 shares. The stock had previously closed at $40.18.
Analyst Ratings Changes
GRAL has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their price objective on shares of Grail from $32.00 to $43.00 and gave the company a "buy" rating in a research report on Wednesday, May 14th. Morgan Stanley boosted their price objective on shares of Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 18th.
Read Our Latest Report on GRAL
Grail Price Performance
The stock's 50 day moving average price is $31.75 and its two-hundred day moving average price is $27.98. The firm has a market capitalization of $1.50 billion and a price-to-earnings ratio of -0.68.
Grail (NASDAQ:GRAL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.03) by $0.93. The company had revenue of $31.84 million for the quarter, compared to the consensus estimate of $35.80 million. As a group, equities research analysts anticipate that Grail, Inc. will post -15.15 EPS for the current fiscal year.
Insider Buying and Selling at Grail
In other Grail news, CFO Aaron Freidin sold 1,816 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $56,659.20. Following the sale, the chief financial officer now owns 335,170 shares of the company's stock, valued at $10,457,304. The trade was a 0.54% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, President Joshua J. Ofman sold 2,109 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total transaction of $65,800.80. Following the completion of the sale, the president now directly owns 559,673 shares in the company, valued at approximately $17,461,797.60. The trade was a 0.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 194,948 shares of company stock valued at $6,583,130 in the last 90 days. 1.85% of the stock is currently owned by company insiders.
Institutional Trading of Grail
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Grail by 37.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company's stock valued at $2,362,000 after purchasing an additional 25,177 shares during the period. Scientech Research LLC acquired a new stake in Grail in the first quarter worth $644,000. NewEdge Advisors LLC raised its holdings in Grail by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock worth $45,000 after purchasing an additional 1,401 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Grail by 28.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company's stock worth $76,000 after purchasing an additional 623 shares during the period. Finally, AQR Capital Management LLC increased its stake in Grail by 61.0% during the 1st quarter. AQR Capital Management LLC now owns 1,337,163 shares of the company's stock worth $33,991,000 after purchasing an additional 506,440 shares in the last quarter.
About Grail
(
Get Free Report)
GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.
Read More
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
